{"id":"d337","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Limited public information is available regarding D337's specific molecular mechanism. As a phase 3 candidate from Chong Kun Dang Pharmaceutical, it has progressed through early clinical testing, but detailed mechanistic data has not been widely disclosed in accessible pharmaceutical databases or literature.","oneSentence":"D337 is an investigational drug in phase 3 development by Chong Kun Dang Pharmaceutical with an undisclosed mechanism of action.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:08:27.086Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT06088017","phase":"PHASE1","title":"A Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetics of CKD-391(2)","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2023-10-23","conditions":"Dyslipidemias","enrollment":66},{"nctId":"NCT06112678","phase":"PHASE1","title":"A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-348(6)","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2024-01-04","conditions":"Hypertension, Dyslipidemias","enrollment":63},{"nctId":"NCT04660370","phase":"PHASE1","title":"A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-348","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2021-01-09","conditions":"Hypertension and Dyslipidemia","enrollment":70},{"nctId":"NCT04883658","phase":"PHASE1","title":"A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-348(2)","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2021-06-04","conditions":"Hypertension and Dyslipidemia","enrollment":62},{"nctId":"NCT05749861","phase":"PHASE1","title":"A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-348(5)","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2023-04-22","conditions":"Hypertension and Dyslipidemia","enrollment":65},{"nctId":"NCT05698043","phase":"PHASE1","title":"A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(5) 80/20/10mg","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2023-07-17","conditions":"Hypertension and Dyslipidemia","enrollment":63},{"nctId":"NCT05634447","phase":"PHASE1","title":"A Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetics of CKD-391","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2022-12-20","conditions":"Dyslipidemias","enrollment":69},{"nctId":"NCT05192356","phase":"PHASE1","title":"A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-348(3)","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2022-02-23","conditions":"Hypertension and Dyslipidemia","enrollment":63},{"nctId":"NCT05549401","phase":"PHASE1","title":"Clinical Trial to Evaluate the Tolerability and the Pharmacokinetics of CKD-348","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2022-09-29","conditions":"Hypertension and Dyslipidemia","enrollment":32},{"nctId":"NCT05552495","phase":"PHASE1","title":"Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-386 in Healthy Volunteers Under Fasting Conditions","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2022-09-23","conditions":"Hypertension and Dyslipidemia","enrollment":31},{"nctId":"NCT05245084","phase":"PHASE1","title":"A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(3) 80/20/10mg","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2022-03-15","conditions":"Hypertension and Dyslipidemia","enrollment":64},{"nctId":"NCT04987970","phase":"PHASE1","title":"A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(2) 80/20/10mg","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2021-09-12","conditions":"Hypertension and Dyslipidemia","enrollment":60},{"nctId":"NCT04312698","phase":"PHASE3","title":"Clinical Trial to Evaluate the Efficacy and Safety of CKD-386","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2019-08-29","conditions":"Dyslipidemia Patients With Hypertension","enrollment":100},{"nctId":"NCT04694989","phase":"PHASE1","title":"A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(2)","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2021-02-20","conditions":"Hypertension and Dyslipidemia","enrollment":62},{"nctId":"NCT04673864","phase":"PHASE1","title":"A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2021-01-17","conditions":"Hypertension and Dyslipidemia","enrollment":66},{"nctId":"NCT04587206","phase":"PHASE1","title":"A Clinical Trial to Evaluate the Pharmacokinetics and Tolerability of CKD-348","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2020-10-15","conditions":"Hypertension and Dyslipidemia","enrollment":62},{"nctId":"NCT04304547","phase":"PHASE1","title":"Clinical Study to Evauate the Pharmacokinetic Profiles and Safety of CKD-348 in Healthy Volunteers","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2020-02-04","conditions":"Healthy","enrollment":15},{"nctId":"NCT04258865","phase":"PHASE1","title":"A Clinical Trial to Compare the Pharmacokinetics and Tolerability of CKD-348","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2020-03-25","conditions":"Hypertension, Dyslipidemias","enrollment":30},{"nctId":"NCT04388215","phase":"PHASE3","title":"Clinical Study to Evaluate the Efficacy and Safety of CKD-348(CKD-828, D326, D337) Tablet","status":"UNKNOWN","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2019-10-23","conditions":"Hypertension, Dyslipidemias","enrollment":120},{"nctId":"NCT04354987","phase":"PHASE1","title":"Compare the Pharmacokinetics and Safety of CKD-391","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2019-10-30","conditions":"Hyperlipidemias","enrollment":44},{"nctId":"NCT04272502","phase":"PHASE1","title":"Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-348 in Healthy Volunteers","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2019-06-04","conditions":"Healthy","enrollment":15},{"nctId":"NCT04223895","phase":"PHASE1","title":"A Clinical Trial to Investigate the Pharmacokinetics and Safety/Tolerability of CKD-386 in Healthy Adult Volunteers","status":"UNKNOWN","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2020-02-01","conditions":"Type2 Diabetes Mellitus","enrollment":30},{"nctId":"NCT03920579","phase":"PHASE1","title":"A Clinical Trial to Investigate the Pharmacokinetics and Safety/Tolerability of CKD-386 in Healthy Male Volunteers","status":"UNKNOWN","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2019-04-01","conditions":"Hypertension, Dyslipidemias","enrollment":30},{"nctId":"NCT03793985","phase":"PHASE1","title":"Compare the Pharmacokinetics and Safety of CKD-391 With Co-administration of D086 and D337","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2018-09-05","conditions":"Hyperlipidemias","enrollment":45},{"nctId":"NCT03726866","phase":"PHASE1","title":"A Study to Investigate Drug-Drug Interaction Between D326, D337 and CKD-828 in Healthy Subjects","status":"UNKNOWN","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2018-08-31","conditions":"Dyslipidemias, Hypertension","enrollment":30},{"nctId":"NCT03609606","phase":"PHASE1","title":"A Study to Investigate Drug Interaction Between D326, D337, and D013 in Healthy Male Subjects","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2018-08-09","conditions":"Dyslipidemias, Hypertension","enrollment":69}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"D337","genericName":"D337","companyName":"Chong Kun Dang Pharmaceutical","companyId":"chong-kun-dang-pharmaceutical","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}